Repros® Has Regained Compliance with Nasdaq Continued Listing Requirements
October 29 2010 - 5:04PM
Business Wire
Repros Therapeutics Inc.® (NasdaqCM:RPRXD) today announced that
it has received a letter from Nasdaq confirming that the Company
has met the minimum bid price requirement for continued listing on
the Nasdaq Capital Market, and Nasdaq has determined to continue
the listing of the Company's securities on the Nasdaq Capital
Market.
As previously announced, the Company had not been in compliance
with Listing Rule 5550(a)(2) requiring the Company to maintain a
minimum $1.00 bid price per share for continued inclusion on the
Nasdaq Capital Market. On October 14, 2010, the Company announced
that it had completed a one-for-four reverse stock split of its
common stock in an effort to regain compliance with the Nasdaq
continued listing requirements. The reverse stock split proved
successful in the Company maintaining its listing on the Nasdaq
Capital Market.
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of oral small
molecule drugs for major unmet medical needs that treat male and
female reproductive disorders.
Any statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including Repros' ability to have the partial hold
on Proellex® lifted and to determine a safe and effective dose for
Proellex, maintain its listing on the NASDAQ Capital Market, raise
needed additional capital on a timely basis in order for it to
continue to fund its operations and pursue its development
activities, and such other risks which are identified in the
Company's most recent Annual Report on Form 10-K and in any
subsequent quarterly reports on Form 10-Q. These documents are
available on request from Repros Therapeutics or at www.sec.gov.
Repros disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more information, please visit the Company's website at
http://www.reprosrx.com.
Repros Therapeutics Inc. (MM) (NASDAQ:RPRXD)
Historical Stock Chart
From May 2024 to Jun 2024
Repros Therapeutics Inc. (MM) (NASDAQ:RPRXD)
Historical Stock Chart
From Jun 2023 to Jun 2024
